Proactive Investors - Creo Medical Group PLC (LON:CREO)'s Speedboat technology is significantly reducing costs and improving patient outcomes in minimally invasive surgeries, according to recent NHS Supply Chain data.
Analysing 130 Speedboat submucosal dissection (SSD) procedures at East Kent University Hospitals Foundation Trust, the report highlighted remarkable reductions in hospital stays and critical care costs compared to traditional surgical methods.
Specifically, it revealed an 87% decrease in the average length of hospital stays, from 8.39 days down to just 1.07 days, and a 99% reduction in critical care costs.
Accommodation costs per patient also saw a drop of 91%, from £3,400 to £300, while admission costs were cut by 62%.
Over one year, overall costs per patient fell by 59%, from £8,800 to £3,600. Additionally, the costs associated with theatre procedures were reduced by 38%.
These efficiencies translated into net cash savings of £687,000 for the NHS trust over the year from the 130 SSD procedures analysed.
These figures do not account for other long-term benefits and cost savings identified through the lifetime horizon Markov model used by Creo, which considers downstream costs related to recurrence and complications often seen with conventional surgeries.
This report comes as NHS Supply Chain, which sources and supplies healthcare services and products, continues its value-based procurement project, aiming to collaborate with the industry to lower overall costs within patient care pathways amidst rising demands and limited resources.
Creo Medical Group's technology is positioned as a beneficial tool in this landscape, promising both economic and health advantages.
"With this data, no longer based on modelling, but gained by looking at every aspect of a comprehensive data set of real cases, we look forward to working closely with NHS Supply Chain to ensure that the successes seen in East Kent University Hospitals with Speedboat are replicated in healthcare settings across the UK," said CREO Craig Gulliford.
"This will enable us to continue to impact on patients and also reducing waiting lists significantly with the level of efficiency improvements this data demonstrates."